二甲双胍与社区居住糖尿病患者阿尔茨海默病风险:全国病例对照研究
结果显示二甲双胍使用(曾经使用)与阿尔茨海默病风险无关(aOR 0.99;95%CI 0.94-1.05),但长期(≥10年)及高累积剂量使用与风险降低相关。
要点
- 二甲双胍曾经使用与阿尔茨海默病风险无关(aOR 0.99;95%CI 0.94-1.05)。
- 使用≥10年者阿尔茨海默病风险降低(aOR 0.85;95%CI 0.76-0.95)。
- 累积剂量>3650 DDDs者风险更低(aOR 0.77;95%CI 0.67-0.88)。
核心结论
- 二甲双胍使用不增加阿尔茨海默病风险,长期高剂量使用与风险降低相关。
主要发现
- 7225例(73.3%)病例和14528名(74.3%)对照至少一次接受二甲双胍。
- 二甲双胍曾经使用与阿尔茨海默病无关(aOR 0.99;95%CI 0.94-1.05)。
- 使用≥10年者阿尔茨海默病风险降低(aOR 0.85;95%CI 0.76-0.95)。
- 累积剂量<1825-3650 DDDs者aOR 0.91(95%CI 0.84-0.98),>3650 DDDs者aOR 0.77(95%CI 0.67-0.88)。
- 平均每日2g二甲双胍者aOR 0.89(95%CI 0.82-0.96)。
临床怎么用
- 对老年糖尿病患者,长期使用二甲双胍不增加阿尔茨海默病风险,且可能具有保护关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Type 2 diabetes has been linked with an increased risk of Alzheimer's disease (AD). Studies on the association between metformin use and AD have reported conflicting results. OBJECTIVE: To investigate whether metformin use modifies the association between diabetes and incident, clinically verified AD. DESIGN: Nested case-control study. SETTING: All community-dwelling people in Finland. PARTICIPANTS: Cases were all community-dwelling Finns with AD diagnosed from 2005 to 2011 and with diabetes diagnosed ≥ 3 years before AD (n = 9862). Cases were matched with up to 2 control persons by age, sex, and diabetes duration (n = 19 550). MAIN OUTCOME MEASURE: Cumulative metformin exposure was determined from reimbursed dispensings over a 10- to 16-year period. Adjusted odds ratios (aORs) were calculated using conditional logistic regression to estimate associations, with adjustment for potential confounders. RESULTS: A total of 7225 (73.3%) cases and 14528 (74.3%) controls received metformin at least once. Metformin use (ever use) was not associated with incident AD (aOR 0.99; 95% confidence interval [CI], 0.94-1.05). The adjusted odds of AD were lower among people dispensed metformin for ≥ 10 years (aOR 0.85; 95% CI, 0.76-0.95), those dispensed cumulative defined daily doses (DDDs) of < 1825-3650 (aOR 0.91; 95% CI, 0.84-0.98) and > 3650 DDDs (aOR 0.77; 95% CI, 0.67-0.88), and among persons dispensed an average of 2 g metformin daily (aOR 0.89; 95% CI, 0.82-0.96). CONCLUSION: In this large national sample we found no evidence that metformin use increases the risk of AD. Conversely, long-term and high-dose metformin use was associated with a lower risk of incident AD in older people with diabetes.
引用
- Sluggett JK, Koponen M, Bell JS, et al. Metformin and Risk of Alzheimer's Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study. J Clin Endocrinol Metab. 2020. PMID: 31778170. doi:10.1210/clinem/dgz234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。